Visceral Leishmaniasis in Latin America and therapy perspectives
Journal: REVISTA MVZ CÓRDOBA (Vol.22, No. 4)Publication Date: 2017-05-03
Authors : Catalina Tovar A María Yasnot A;
Page : 6075-6088
Keywords : Disease; drug therapy; Leishmania infantum; Lutzomyia; vector;
Abstract
In Latin America, visceral leishmaniasis is caused by Leishmania infantum. In this geographical area, main vectors associated with transmission are Lutzomyia longipalpis and Lutzomyia evansi, with dogs being incriminated as the main reservoir involved in transmission of the disease. This pathology primarily affects children between 0 - 5 years, a highly susceptible population where socio-economic, environmental and nutritional factors affects the pathological outcome and increase the likelihood of vector-human contact. According to the World Health Organization (WHO) recommended treatment for Visceral Leishmaniasis is liposomal amphotericin B, a drug with a limited and variable availability between countries depending on market prices, which leaves pentavalent antimonial as the most widely used treatment despite the associated toxic effects. In the Americas, evidence on the efficacy of single-dose (monotherapy) and combination therapies as options for treating these parasites is required.
Other Latest Articles
- Pharmacokinetics and adverse effects of doxycycline in the treatment of Ehrlichiosis: theoretical foundations for clinical trials in canines
- Effect of the use of fluazuron for control of Rhipicephalus (Boophilus) microplus in cattle
- Phlebotomine sandflies (Diptera: Psychodidae) collected in rural area from San Bernardo del Viento (Córdoba, Colombia)
- A global graphical picture of the wear depth in dry contact between composite polymer and steel
- Analysis of epidemiological indicators: Bovine brucellosis on the Atlantic coast and Antioquia - Colombia, 2005-2013
Last modified: 2017-11-23 23:24:16